Current SATVI news
We have a vacancy for a Research Pharmacist at our Worcester Field site. NOW CLOSED
On Friday 17 November 75 ministers announced a landmark agreement to take urgent action to end tuberculosis (TB) by 2030 at the conclusion of a World Health Organization (WHO) conference in Moscow, Russia, on eradicating the world's deadliest infectious disease.
Associate Professor Tom Scriba has collaborated with the authors of a research paper titled: "TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development" appearing in the Frontiers in Immunology Journal.
Associate Professor Tom Scriba has co authored a research paper titled "Polyfunctional CD4+T Cells as targets for Tuberculosis Vaccination" appearing in the Frontiers in Immunology Journal.
SATVI authors Dr Elisa Nemes, Prof Mark Hatherill, Associate Prof Tom Scriba, Dr Michele Tameris, Humphrey Mulenga and Danelle Van As have published a research paper titled: "Safety and Immunogenicity of newborn MVA 85 A vaccination and selective delayed Bacille Calmette-Guerin for infants of HIV infected mothers: a Phase 2 randomized controlled trial" appearing in the Infectious Disease Journal (Oxford).
Associate Professor Tom Scriba has co-authored a article titled: "Host blood RNA predict the outcome of tuberculosis treatment" appearing in the Tuberculosis Journal.
SATVI invites applications for the position of Research Officer: Systems Immunology at its Cape Town offices. CLOSED.
SATVI authors have published a research paper titled: "Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population" appearing in the PLoS ONE Journal.
Professor Mark Hatherill and Associate Professor Tom Scriba have co-authored a research paper titled "A Functional Toll-interacting Protein variant with Bacillus Calmette-Guerin specific immune responses and Tuberculosis" appearing in the American Journal of Respiratory and Critical Care Medicine.
Associate Professor Tom Scriba has co-authored a research paper titled "Identifying specificity groups in the T Cell receptor repertoire" appearing in the Nature Journal.
SATVI authors Associate Professor Tom Scriba, Dr Stanley Mbandi Kimbung, Fatoumatta Darboe and Dr Adam Penn-Nicholson have co-authored a paper titled "Protein kinase C-delta (PKCd), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice" appearing in the Mucosol Immunology Journal.
SATVI recently marked the 3 000th patient who had been screened for participation in the Correlates of Risk of TB study (CORTIS-01).